Complete Genomics Launches Cancer Grant Program
June 29 2011 - 8:00AM
Complete Genomics Inc. (Nasdaq:GNOM), a complete human genome
sequencing company, today announced that it is introducing a new
cancer grant program. Winning research applications will receive
complete human genome sequencing of eight genomes — four
tumor/normal pairs. Four winning entries will be chosen: two each
from the United States and Europe.
Complete Genomics is accepting grant applications
for cancer-specific research projects using its complete human
genome sequencing service from now until July 29, 2011.
Applications will be evaluated by an internal panel of scientific
experts at Complete Genomics. Winners will be notified by Aug. 12
and will be required to submit their samples by Sept. 16. In
addition, all applicants will be automatically eligible for a
discount on their next complete human genome sequencing
project.
"We designed this grant program to recognize and
reward those scientists who are developing innovative cancer
research projects," said Dr. Clifford Reid, chairman, president and
CEO of Complete Genomics. "We are delighted to have the opportunity
to provide pioneering scientists with complete human genome
sequencing and research-ready data that they can immediately use to
gain insights into the characterization and possible treatment of
various cancers."
For more information about the grant program or to
submit an application, please visit at
http://www.completegenomics.com/news-events/grant-program/.
About Complete Genomics
Complete Genomics is a complete human genome
sequencing company that has developed and commercialized an
innovative DNA sequencing platform. The Complete Genomics Analysis
Platform (CGA™ Platform) combines Complete Genomics' proprietary
human genome sequencing technology with our advanced informatics
and data management software. We offer this solution as an
innovative, end-to-end, outsourced service, CGA™ Service, and
provide customers with data that is immediately ready to be used
for genome-based research. Additional information can be found at
http://www.completegenomics.com.
The Complete Genomics logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8216
Forward-Looking Statements
Certain statements in this press release, including
statements relating to the ability of scientists to use the genome
sequencing data that we provide to them to immediately gain
insights into the characterization and possible treatment of
various cancers are forward-looking statements that are subject to
risks and uncertainties. Readers are cautioned that these
forward-looking statements are based on management's current
expectations, and actual results may differ materially from those
projected. The following factors, without limitation, could
cause actual results to differ materially from those in the
forward-looking statements: the ability of scientists to
successfully analyze the genomic data we provide; and the ability
of researchers to convert genomic data into medically valuable
information. More information on potential factors that could
affect the usefulness of the genomic data that we provide to our
customers is included in our Securities and Exchange Commission
filings and reports, including the risks identified under the
section captioned "Risk Factors" in our Registration Statement on
Form S-1 filed on May 18, 2011. We disclaim any obligation to
update information contained in these forward-looking statements,
whether as a result of new information, future events or
otherwise.
CONTACT: Complete Genomics Inc.
Jennifer Turcotte
Vice President of Marketing
(650) 943-2846
jturcotte@completegenomics.com
Waggener Edstrom Worldwide
Healthcare
Lisa Osborne
Account Director
(202) 261-7806
completegenomics@waggeneredstrom.com
Global X Genomics and Bi... (NASDAQ:GNOM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Global X Genomics and Bi... (NASDAQ:GNOM)
Historical Stock Chart
From Jul 2023 to Jul 2024